Abstract

Splenic lymphocytes play an important role in host acute or chronic diseases. The abnormality of these cells in the spleens of humans might lead to some riskful diseases for human. Hence, in this study, the effects of two ginsenosides Rg1 and Rb1 on splenic lymphocytes growth were studied by microcalorimetry. Some qualitative and quantitative information, such as the metabolic power-time curves, growth rate constant k, maximum heat-output power of the exponential phase P max, total heat output Q t of splenic lymphocytes were obtained to present the effects of Rg1 and Rb1 on these cells. The values of k, P max, and Q t from the thermogenic growth curves of splenic lymphocytes were found to increase in the presence of Rg1, while the change was adverse for Rb1, illustrating that Rg1 had promotion effect and Rb1 had inhibitory effect on splenic lymphocytes growth and these promotion or inhibitory effects were enhanced with increasing the concentration of the two compounds, respectively. The microcalorimetric results were confirmed by MTT assay for determining the MTT optical density (OD) value and [3H] Thymidine incorporation assay ([3H]-TdR) for determining the count per minute (cpm) value: Rg1 could increase the MTT OD value and the cpm value of [3H]-TdR incorporation into splenic lymphocytes, and these values were increased with increasing the concentration of this compound, while Rb1 had the adverse results. The structure–activity relationships showed that the glucopyranoside and hydroxyl groups at the dammarane-type mother nucleus skeleton might play a crucial role for the opposing effects of the two ginsenosides on splenic lymphocytes. Compared with the other two assay methods, the microcalorimetric method provided more useful and reliable information for quickly and objectively evaluating the effects of drugs or compounds on the living cells, which would be a highly promising analytical tool for the characterization of the biological process and the estimation of the drugs’ efficiency.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.